Newswire (Published: Tuesday, June 6, 2017, Received: Friday, June 2, 2017, 2:38:29 AM CDT)

Word Count: 420

Findings from University of Manitoba Reveals New Findings on Prostate Cancer (Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups)

By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology - Prostate Cancer is now available. According to news reporting originating from Winnipeg, Canada, by NewsRx correspondents, research stated, "To combine circulating tumor cell (CTC) isolation by filtration and immunohistochemistry to investigate the presence of CTCs in low, intermediate, and high-risk prostate cancer (PCa). CTCs isolated from these risk groups stained positive for both cytokeratin and androgen receptors, but negative for CD45."

Our news editors obtained a quote from the research from the University of Manitoba, "Blood samples from 41 biopsy confirmed patients with PCa at different clinical stages such as low, intermediate, and high risk were analyzed. The samples were processed with the ScreenCell filtration device and PCa CTCs were captured for all patients. The isolated CTCs were confirmed PCa CTCs by the presence of androgen receptors and cytokeratins 8, 18, and 19 that occurred in the absence of CD45 positivity. PCa CTC nuclear sizes were measured using the TeloView program. The filtration-based isolation method used permitted the measurement of the average nuclear size of the captured CTCs. CTCs were identified by immunohistochemistry in low, intermediate, and high-risk groups of patients with PCa. CTCs may be found in all stages of PCa."

According to the news editors, the research concluded: "These CTCs can be used to determine the level of genomic instability at any stage of PCa; this will, in the future, enable personalized patient management."

For more information on this research see: Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups. Urologic Oncology-Seminars and Original Investigations, 2017;35(5):300-309. Urologic Oncology-Seminars and Original Investigations can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA (see also Oncology - Prostate Cancer).

The news editors report that additional information may be obtained by contacting S. Mai, University of Manitoba, Cancer Care Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E OV9, Canada. Additional authors for this research include J. Saranchuk, D. Drachenberg and J.A. Awe.

Keywords for this news article include: Winnipeg, Manitoba, Canada, North and Central America, Metastatic Prostate Cancer, Cancer, Epidemiology, Risk and Prevention, Prostatic Neoplasms, Cancer Risk, Oncology, Genetics, University of Manitoba.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

University of Manitoba
ScreenCell

Places

Central America
North America
Canada
United States
Americas
Manitoba
New York
Winnipeg
New York City

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Genetics
            Medical Research
                  Clinical Outcomes